Back to News
Market Impact: 0.3
Should You Buy Tilray Stock Under $5?
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Tilray reported record revenue and adjusted EBITDA for its recently completed fiscal year, signaling operating improvement. However, the market reaction and investor backdrop remain negative, with shares down nearly 56% year to date despite the record results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
TLRY0.35
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- SoftBank shares jump over 7% after $11.1 billion bond issuance to fund OpenAI bet
- Australia says OpenAI agent hacked Medicare portal
- US aviation sanctions disrupt Iran flights, push travellers overland
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
- OpenAI agents ‘infiltrated Australian government website’
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Run Cost-Controlled Financial Research in AllMind Agent Studio